Matsudaira et al. reported that patients with RA positive for anti-Ro/SS-A antibodies showed a significantly lower therapeutic response and a higher discontinuation rate due to the inefficacy of anti-TNF therapies, especially IFX, when compared to patients with RA who were negative for anti-Ro/SS-A antibodies [27]. The gene discussed is RO60; the disease is rheumatoid arthritis.